Papers: 10.1371/journal.pone.0236345

https://doi.org/10.1371/journal.pone.0236345

Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018

Cited by: 13
Author(s): Tatiane Bomfim Ribeiro, Lewis Buss, Cole Wayant, Moacyr Roberto Cucê Nobre
Published: about 6 years ago

Software Mentions 1